Literature DB >> 20689329

Experimental peritoneal sclerosis models should not be based on chlorhexidine gluconate anymore.

Anniek Vlijm1, Denise E Sampimon, Marijke de Graaff, Dirk G Struijk, Raymond T Krediet.   

Abstract

BACKGROUND/AIMS: Currently available rodent models of peritoneal sclerosis are not based on clinically relevant factors: renal failure in combination with exposure to bioincompatible fluids. Our aim was to develop a chronic peritoneal infusion model of peritoneal sclerosis in rats with renal failure.
METHODS: Male Wistar rats underwent a catheter implantation and a 70% nephrectomy. They were randomly divided into three peritoneal infusion groups: chlorhexidine gluconate/ethanol (CGE) + Dianeal (Baxter Healthcare, Castlebar, Ireland), CGE + buffer (Physioneal without glucose; Baxter, Nivelles, Belgium) and Dianeal alone. After 8 weeks a peritoneal permeability test was performed and omental tissue was obtained for morphometrics.
RESULTS: The CGE + Dianeal group (n = 6) and CGE + buffer (n = 6) group showed high peritoneal clearances of small solutes and proteins, ultrafiltration failure, impaired free water transport, severe fibrosis and high vessel counts, but the groups did not differ significantly. The Dianeal group (n = 6) showed significantly lower clearances of small solutes and proteins, normal ultrafiltration and sodium sieving, and significantly lower fibrosis scores and vessel counts.
CONCLUSIONS: Abnormalities seen in peritoneal sclerosis can be induced in a peritoneal infusion model in rats with renal failure. However, the addition of a bioincompatible dialysis solution had no contributing role, probably because the effects were overruled by those of CGE.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20689329     DOI: 10.1159/000319651

Source DB:  PubMed          Journal:  Nephron Exp Nephrol        ISSN: 1660-2129


  6 in total

1.  Can effluent matrix metalloproteinase 2 and plasminogen activator inhibitor 1 be used as biomarkers of peritoneal membrane alterations in peritoneal dialysis patients?

Authors:  Deirisa Lopes Barreto; Annemieke M Coester; Dirk G Struijk; Raymond T Krediet
Journal:  Perit Dial Int       Date:  2013-09-01       Impact factor: 1.756

2.  Peritoneal fibrosis and high transport are induced in mildly pre-injured peritoneum by 3,4-dideoxyglucosone-3-ene in mice.

Authors:  Hideki Yokoi; Masato Kasahara; Kiyoshi Mori; Takashige Kuwabara; Naohiro Toda; Ryo Yamada; Shinji Namoto; Takashi Yamamoto; Nana Seki; Nozomi Souma; Taku Yamaguchi; Akira Sugawara; Masashi Mukoyama; Kazuwa Nakao
Journal:  Perit Dial Int       Date:  2012-11-01       Impact factor: 1.756

3.  An intra-abdominal abscess or "rind" as a consequence of peritoneal dialysis-associated pseudomonas peritonitis.

Authors:  R Michael Culpepper; Sarah Gore; Gregory W Rutecki
Journal:  Clin Nephrol Case Stud       Date:  2013-02-26

4.  Novel Application of Magnetite Nanoparticle-Mediated Vitamin D3 Delivery for Peritoneal Dialysis-Related Peritoneal Damage.

Authors:  Fong-Yu Cheng; Yuan-Yow Chiou; Shih-Yuan Hung; Tsun-Mei Lin; Hao-Kuang Wang; Chi-Wei Lin; Hung-Hsiang Liou; Min-Yu Chang; Hsi-Hao Wang; Yi-Che Lee
Journal:  Int J Nanomedicine       Date:  2021-03-11

5.  Use of paclitaxel carried in solid lipid nanoparticles to prevent peritoneal fibrosis in rats.

Authors:  Filipe M O Silva; Priscila O Carvalho; Elerson C Costalonga; Rafael Pepineli; Raul C Maranhão; Irene L Noronha
Journal:  PLoS One       Date:  2022-05-06       Impact factor: 3.752

6.  Vitamin D can ameliorate chlorhexidine gluconate-induced peritoneal fibrosis and functional deterioration through the inhibition of epithelial-to-mesenchymal transition of mesothelial cells.

Authors:  Yi-Che Lee; Shih-Yuan Hung; Hung-Hsiang Liou; Tsun-Mei Lin; Chu-Hung Tsai; Sheng-Hsiang Lin; Yau-Sheng Tsai; Min-Yu Chang; Hsi-Hao Wang; Li-Chun Ho; Yi-Ting Chen; Ching-Fang Wu; Ho-Ching Chen; Hsin-Pao Chen; Kuang-Wen Liu; Chih-I Chen; Kuan Min She; Hao-Kuang Wang; Chi-Wei Lin; Yuan-Yow Chiou
Journal:  Biomed Res Int       Date:  2015-10-01       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.